The global animal health sector is experiencing significant shifts driven by long-acting biopharmaceuticals, evolving distribution channels, and persistent biosecurity challenges. Industry projections see the global animal health market expanding toward $60 billion to $90 billion in the coming years, fueled by companion animal therapies and livestock productivity solutions.
1. Major Product & Therapeutics Developments
Zoetis Launches Long-Acting Canine OA Therapy (Lenivia®)
Zoetis UK announced the official commercial launch of Lenivia® (izenivetmab injection) in Great Britain.
-
Mechanism: Lenivia is a long-acting anti-Nerve Growth Factor (NGF) monoclonal antibody designed to alleviate osteoarthritis (OA) pain in dogs
-
Extended Dosing Window: Unlike first-generation monthly mAb therapies, a single subcutaneous injection of Lenivia provides sustained pain reduction for up to three months
-
Clinical Impact: Pivotal field data demonstrated pain reduction starting as early as Day 7 post-injection. The extended dosing interval aims to directly address veterinary and pet-owner compliance friction in managing chronic canine pain
Elanco Highlights R&D Momentum and Biomanufacturing Expansion
At the Bank of America Global Healthcare Conference, Elanco Animal Health outlined key milestones across its companion animal portfolio:
-
First-Line Adoption: Its dermatology product Zenrelia has grown to become a first-line treatment for over 40% of surveyed veterinarians, up from under 20% a year ago
-
Fastest Blockbuster: Parasiticide Credelio Quattro became the fastest product to reach blockbuster status in Elanco’s 71-year history.
-
Scaling Monoclonal Antibodies: To meet demand for Befrena (an anti-allergy mAb), Elanco is scaling manufacturing capacity from 200-liter bioreactors to 2,000-liter and 5,000-liter facilities
2. Market Dynamics & Retail Transformation
Metric / Trend |
Current Industry Data |
Strategic Impact |
E-Commerce Growth |
Growing 2x faster than in-clinic veterinary purchases |
Forces pharmaceutical manufacturers to diversify distribution strategies beyond traditional clinic networks |
Over-the-Counter Sourcing |
~33% of pet owners buy health products online/OTC without a vet visit |
Increases demand for direct-to-consumer educational campaigns and clear OTC product labeling |
Pet Population Trends |
U.S. pet counts remain largely flat, while ~70% of new puppies are outside the U.S. |
Accelerates global expansion into high-growth international affiliate markets |
3. Livestock & Global Biosecurity Surveillance
-
Avian Influenza Surveillance: European agricultural and veterinary monitoring agencies reported over 7,100 outbreaks of avian influenza in wild bird, commercial poultry, and backyard populations across 35 reporting nations.
-
African Swine Fever (ASF) in Wild Boar: Systematic monitoring across Europe continues to track wild boar infection vectors. Veterinary authorities are expanding partnerships with hunting communities and forest managers for early carcass detection and biosecurity containment.
-
Sustainability & Protein Productivity: Livestock health providers are increasing focus on environmental productivity solutions—such as feed additives designed to reduce enteric methane and ammonia emissions while maintaining herd yields.
Key Industry Indicators
-
Companion Animal Sector: Generates ~40% of overall industry revenue, driven by longevity treatments and dermatological innovations.
-
Livestock Sector: Generates ~60% of industry revenue, anchored by disease control and sustainability metrics.
References & Sources
-
Zoetis Inc. (2026). Zoetis Launches Lenivia® (izenivetmab injection) in Great Britain. Press Release.
-
Elanco Animal Health. (2026). Presentation at the Bank of America Global Healthcare Conference. Financial & Portfolio Outlook.
-
FACE (Federation for Associations for Hunting and Conservation of the EU). (2026). Animal Health Updates: Avian Influenza and African Swine Fever Surveillance Data.
